Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.52 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.45 |
| ▸ | PARP1 | P09874 | 7/20 | 0.44 |
| ▸ | IP6K1 | Q92551 | 7/20 | 0.42 |
| ▸ | IP6K3 | Q96PC2 | 4/20 | 0.42 |
| ▸ | IP6K2 | Q9UHH9 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9195848 | 0.77 | SMN1; SMN2 (0.67) | SLC2A1ACVR1PARP1IP6K1IP6K3 | |
| SCHEMBL14927302 | 0.75 | HPD (0.46) | — | |
| SCHEMBL14927300 | 0.75 | ELANE (0.44) | SMN1; SMN2CHEK1KDM4EALDH1A1HPGD | |
| SCHEMBL14927291 | 0.74 | ELANE (0.44) | SMN1; SMN2CHEK1KDM4EALDH1A1HPGD | |
| SCHEMBL14927289 | 0.73 | ADORA3 (0.43) | SMN1; SMN2CA12CA9KDM4EALDH1A1 | |
| SCHEMBL15094046 | 0.72 | RAB9A (0.42) | SMN1; SMN2CHEK1KDM4EALDH1A1HPGD | |
| SCHEMBL263154 | 0.71 | SLC2A1 (0.74) | SLC2A1ACVR1PARP1IP6K1IP6K3 | |
| SCHEMBL327753 | 0.70 | KDM4E (0.41) | KDM4EALDH1A1HPGDHTTRAB9A | |
| SCHEMBL4179088 | 0.70 | SLC2A1 (0.72) | SLC2A1ACVR1PARP1IP6K1IP6K3 | |
| SCHEMBL3845750 | 0.70 | SLC2A1 (0.72) | SLC2A1ACVR1PARP1IP6K1IP6K3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590976-B1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2015-09-16 | — | — | EP | claimed |
| US-8759344-B2 | Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-06-24 | — | — | US | claimed |
| US-20130116250-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-09 | — | — | US | claimed |
| US-9732078-B2 | Therapeutic use of imidazopyridine derivatives | SANOFI (FR) | 2017-08-15 | — | — | US | disclosed |
| US-9452164-B2 | Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof | SANOFI (FR) | 2016-09-27 | — | — | US | disclosed |
| CN-103080111-B | Imidazopyridine derivatives, its preparation method and therapeutical uses thereof | 赛诺菲 | 2016-06-15 | — | — | CN | disclosed |
| EP-2800566-B1 | THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES | SANOFI SA (FR) | 2015-10-28 | — | — | EP | disclosed |
| EP-2590976-B1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2015-09-16 | — | — | EP | disclosed |
| US-20140343054-A1 | Therapeutic Use of Imidazopyridine Derivatives | SANOFI (FR) | 2014-11-20 | — | — | US | disclosed |
| EP-2800566-A1 | THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES | SANOFI (FR) | 2014-11-12 | — | — | EP | disclosed |
| CN-104144687-A | THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES | SANOFI SA | 2014-11-12 | — | — | CN | disclosed |
| US-20140243328-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-08-28 | — | — | US | disclosed |
| US-8759344-B2 | Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-06-24 | — | — | US | disclosed |
| WO-2013102860-A1 | THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES | SANOFI (FR) | 2013-07-11 | — | — | WO | disclosed |
| EP-2590976-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-15 | — | — | EP | disclosed |
| US-20130116250-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-09 | — | — | US | disclosed |
| WO-2012004732-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243328-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CCNY, ENY2, PAH | SLC2A1 3810/4885ACVR1 2197/4885PARP1 80/4885 |
| US-20140343054-A1 | Therapeutic Use of Imidazopyridine Derivatives | CCNY, UTS2R, WNK2 | SLC2A1 3292/4885ACVR1 1837/4885PARP1 499/4885 |
| US-20130116250-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CCNY, ENY2, PAH | SLC2A1 3810/4885ACVR1 2197/4885PARP1 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.